Clarity enhances its pipeline with Cu-64 67 SAR trastuzumab

Clarity Pharmaceuticals (ASX: CU6) has expanded its Targeted Copper Theranostic portfolio by adding 64/67Cu-SAR-trastuzumab. This novel asset, developed using Clarity’s SAR Technology, targets HER2-positive cancers, particularly breast cancer. Pre-clinical data demonstrated that 64Cu-SAR-trastuzumab effectively binds to HER2-expressing cancer cells, while 67Cu-SAR-trastuzumab significantly reduces tumour growth and improves survival in a dose-dependent manner.

Clarity has signed a Supply Agreement with EirGenix, Inc. to support clinical development for the clinical-grade GMP trastuzumab biosimilar EG12014. HER2 is present in up to 20% of breast cancers, contributing to aggressive tumour progression. Clarity’s renewed focus on breast cancer is reinforced by its SAR-Bombesin, SARTATE, and SAR-bisPSMA products. With strong clinical trial capabilities in the US and Australia, Clarity is well-positioned to advance this groundbreaking radiopharmaceutical towards clinical translation, addressing a critical need in HER2-positive breast cancer treatment.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com